U.S. Appeals Court Blocks Trump Era 340B Drug Discount Pilot Program
The court's decision pauses the rollout of a controversial pilot that aimed to reform drug pricing for hospitals under the 340B program. This legal development underscores persistent challenges in federal drug rebate policies.
Background
- The 340B program provides discounted drug prices to certain hospitals and health providers.
- The Trump administration's pilot sought to alter how rebates were handled under this program.
Court Ruling
- A U.S. appeals court panel ruled against allowing the pilot program to proceed for now.
- This decision temporarily prevents changes to the existing drug discount framework.
Significance
The ruling highlights the complexity and regulatory scrutiny surrounding federal drug pricing initiatives, particularly ones that impact hospital funding and pharmaceutical rebates.
Source
Trump administration 340B pilot program is thwarted, for now, by a U.S. appeals court
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.